Singapore markets close in 6 hours 39 minutes
  • Straits Times Index

    3,181.13
    -27.73 (-0.86%)
     
  • Nikkei

    31,309.25
    -450.63 (-1.42%)
     
  • Hang Seng

    17,275.39
    -534.27 (-3.00%)
     
  • FTSE 100

    7,510.72
    -97.36 (-1.28%)
     
  • Bitcoin USD

    27,553.72
    -413.65 (-1.48%)
     
  • CMC Crypto 200

    589.65
    -13.89 (-2.30%)
     
  • S&P 500

    4,288.39
    +0.34 (+0.01%)
     
  • Dow

    33,433.35
    -74.15 (-0.22%)
     
  • Nasdaq

    13,307.77
    +88.45 (+0.67%)
     
  • Gold

    1,835.50
    -11.70 (-0.63%)
     
  • Crude Oil

    87.87
    -0.95 (-1.07%)
     
  • 10-Yr Bond

    4.6830
    +0.1100 (+2.41%)
     
  • FTSE Bursa Malaysia

    1,421.06
    +2.30 (+0.16%)
     
  • Jakarta Composite Index

    6,965.13
    +3.67 (+0.05%)
     
  • PSE Index

    6,270.54
    -33.99 (-0.54%)
     

Novavax's New CEO Leads Vaccine Trial Success, and Big Layoffs Too

Novavax's New CEO Leads Vaccine Trial Success, and Big Layoffs Too

Novavax (NASDAQ: NVAX) investors have been on edge ever since the company fell behind in the coronavirus vaccine race. To make matters worse, earlier this year, Novavax even questioned its ability to continue operations. Jacobs revealed details about his strategy to cut costs, manage cash flow, and match Novavax's size to the demand for its only product: the coronavirus vaccine.